Premium
Novel treatment of Sézary‐like syndrome due to adult T‐cell leukaemia/lymphoma with daclizumab (humanized anti‐interleukin‐2 receptor α antibody)
Author(s) -
Osborne G.E.N.,
Pagliuca A.,
Ho A.,
Du Vivier A.W.P.
Publication year - 2006
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.2006.07355.x
Subject(s) - medicine , daclizumab , hematology , dermatology , family medicine , transplantation , tacrolimus
Summary We describe a patient with erythrodermic adult T‐cell leukaemia/lymphoma resistant to multiple systemic therapies who, on the commencement of daclizumab, a humanized anti‐interleukin‐2 receptor antibody, developed a rapid and sustained complete response with resolution of previously debilitating erythroderma, suggesting significant activity of this agent in this disease process.